Structure of the anti-cancer drug complex tetrakis (mu-acetato)-bis(1-methyladenosine)dirhodium(II) monohydrate.
[Rh2(C2H3O2)4(C11H16N5O4)2].H2O, Mr = 1024.6, triclinic, P1, a = 7.808 (3), b = 11.469 (4), c = 12.091 (2) A, alpha = 69.55 (2), beta = 79.46 (2), gamma = 76.61 (3) degrees, V = 980.7 (6) A3, Z = 1, Dx = 1.735 g cm-3, lambda (Cu K alpha) = 1.5418 A, mu = 77.6 cm-1, F(000) = 522, room temperature, R = 0.053 for 3638 unique reflections. Structure consists of two rhodium(II) ions in a metal--metal bond bridged by four acetate groups. The remaining axial coordination sites on the rhodium ions are coordinated to the N(7) positions of two 1-methyladenosine molecules.
Rubin
J R
JR
NCI-FCRF, Frederick, MD 21701.
Haromy
T P
TP
Sundaralingam
M
M
D000241:Adenosine / Q000031:analogs & derivatives* / Q000737:chemistry; D000970:Antineoplastic Agents / Q000737:chemistry*; D009942:Organometallic Compounds / Q000737:chemistry*; D012238:Rhodium / Q000737:chemistry*; D014961:X-Ray Diffraction
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; C072767:tetrakis(mu-aceto)-bis(1-methyladenosine)dirhodium (II); D012238:Rhodium; D000241:Adenosine